Mandibular solitary plasmocytoma of the jaw : a case report by Rodríguez Caballero, B. et al.
Med Oral Patol Oral Cir Bucal. 2011 Aug 1;16 (5):e647-50.                                                                                                                                                                            Mandibular plasmocytoma
e647
Journal section: Oral Medicine and Pathology
Publication Types: Case Report
Mandibular solitary plasmocytoma of the jaw: A case report
Beatriz Rodríguez-Caballero 1, Sergio Sanchez-Santolino 1, Belén García-Montesinos-Perea 1, Maria-Fe Gar-
cia-Reija 1, Javier Gómez-Román 2,  Ramon Saiz-Bustillo 3
1 Oral and Maxillofacial Surgeon, University Hospital “Marqués de Valdecilla” (Santander, Cantabria, Spain)
2 Medical Pathologyst, University Hospital “Marqués de Valdecilla” (Santander, Cantabria, Spain) 
3 Chief of Oral and Maxillofacial Surgery, University Hospital “Marqués de Valdecilla” (Santander, Cantabria, Spain)
Correspondence:
Avda. Oviedo N º 9 Edif 2 Bj B, 





Plasma cell tumors are lymphoid neoplasms with an uncontrolled proliferation of B cells. These are divided into 
localized forms (solitary bone plasmocytoma -SBP- and extramedullary plasmocytoma -EP-) and disseminated 
forms (multiple myeloma–MM-). The SBP is a rare and controversial disease. The aim of this article is the analysis 
of this entity based on the presentation of a 64-year-old man without previous medical history, with a mass in the 
left mandibular angle extending to the parotid region on the same side. The panoramic radiography, computed 
tomography and magnetic resonance imaging showed an osteolytic lesion  6.5 x 5 x 6.7 cm in the mandibular 
angle with infiltration of the masticator space and left parotid region. The normality of the extension study, and 
histopathological examination confirmed the diagnosis of SBP. The patient received treatment with radiotherapy 
with good outcome. 
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Plasma cell neoplasms are a group of clinical disorders 
characterized by an uncontrolled monoclonal prolifera-
tion of plasma cells or plasma cells derived (stem cells 
and lymphoid cell line B)  and, in the case of multiple 
myeloma, by monoclonal overproduction of immunog-
lobulins in blood and / or detecting light chains in the 
urine  as Bence Jones protein (1-3). The incidence of the-
se  tumors is about 2,6-3,3 per 100,000 population being 
higher in blacks. The average age of presentation is in 
the sixth decade of life (2). Localized forms of plasma 
cells neoplasms are solitary bone plasmacytoma (SBP) 
and extramedullary plasmocytoma (EMP), multiple 
myeloma (MM) is the disseminated type of this disor-
der (1-5). In the maxillofacial area plasmocytoma may 
be divided into different clinical forms: a manifestation 
of disseminated disease (MM), a solitary lesion in the 
soft tissues (often in the parotid gland) or a solitary bone 
lesion with or without invasion of local structures (as in 
the case presented) (6-8). 
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The biological behaviour of these tumors is variable, 
from periods of clinical latency to rapid growth and 
progression from the localized forms (SBP and EMP) 
to (MM). EMP has a better prognosis because 30% 
progress to MM compared with 70% in SBP (1,2,5). 
Many authors have considered SBP as an early mani-
festation of MM. This article presents a brief general 




A 64-year-old male consulted the Department of Oral 
and Maxillofacial Surgery, University Hospital Mar-
qués de Valdecilla (Santander) in January 2008 with 
the primary complaint of a painless swelling in the left 
preauricular region that he had first noticed 1 month 
before. The patient’s surgical history included removal 
of a remnant root in his left lower jaw two weeks befo-
re. The physical examination showed a firm, no mobile 
mass measuring approximately 5 cm in its greatest di-
mension in the left preauricular region to the mandibu-
lar angle. Neurologic examination of cranial nerves V 
and VII was normal without visible skin changes. The 
oral examination showed a slight bulging on the man-
dibular angle covered with normal oral mucosa. The 
mouth opening pattern was 4.5 cm. without laterode-
viation and / or clicking on the left temporomandibular 
joint (Fig. 1). 
Panoramic radiography showed an ill-defined, mul-
tilocular, radiolucent mass in the left mandibular angle 
and ramus. Ultrasound of salivary glands revealed on 
the superficial lobe of left parotid gland a lesion, 5,8cm 
in its greatest diameter, with peripheral desmoplastric 
reaction. Doppler study were performed demonstrated 
no significant increase in vascularization. The Com-
puterized Tomography (CT) and Magnetic Resonance 
(MRI) showed a 6.5 x 5 x 6.7 cm. destructive mass that 
extended from the posterior third of the mandibular 
body to the ramus with infiltration of the masticatory 
space and parotid gland (Figs 2A and B). 
Aspiration cytology was not conclusive, so an incisional 
biopsy was performed under general anesthesia. The his-
tology confirmed the diagnosis of CD 138 + bone plas-
macytoma with kappa light chain restriction (Fig. 3). 
The patient was them referred to haematology de-
partment.  A skeletal radiographic survey was obtai-
ned and showed no other osteolytic lesions. Laboratory 
analysis of the patient’s blood and urine revealed no mo-
noclonal gammopathy or Bence Jones protein. 
Fig. 1. Tumor extending from left mandibular 
angle to the parotid region. 
Fig. 2A. MRI coronal section. 
Fig. 2B. 3D CT. 
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The results of medulogram confirmed a 3% atypical 
plasma cells. The skeletal survey as well as laboratory 
investigations confirmed the diagnosis of solitary bone 
plasmacytoma. The patient was treated with local ra-
diotherapy to a dose of 45 Gy, with good outcome. One 
year after finishing the treatment the patient is asymp-
tomatic and without signs of recurrence. 
 
Discussion
 Solitary bone plasmacytoma is a localized malignant 
monoclonal gammopathy which constitutes approxima-
tely 3-10% of all plasma cell tumours (1,2). The peak 
incidence is in the sixth decade of life, being more 
prevalent in male than females with a ratio 2:1(1). The 
most common sites of SBP are the vertebrae, long bones 
and skull. It is  rarely involved the maxillofacial area 
most commonly in the mandible, especially in the bone 
marrow-rich areas: the retromolar trigone, angle and ra-
mus (4.5). Local clinical signs and symptoms are bone 
swelling, localized pain in the jaws and teeth, numb-
ness and / or anesthesia, bleeding, tooth mobility and 
possible bone fracture. Involvement of local mucosa or 
tissues, as in our case, it can also be seen. Fatigue or 
fever are the most common systemic symptoms (5-7). 
Radiographically SBP is seen as a well defined uni or 
multilocular lytic lesion without periosteal reaction (4), 
or as a protruding mass with cortical expansion (6).CT, 
MRI and more recently PET, are useful to establish the 
characteristics of the lesion and tissues involved and to 
rule out other affected areas (4,7). 
Diagnosis is based on the presence of malignant proli-
feration of plasma cells in the biopsy, absence of further 
osteolytic bone lesions (mainly, in the iliac crest and 
sternum), histologically normal marrow aspirate and 
absence or low concentrations of serum or urine mono-
clonal protein. The last criterion to confirm the diagno-
sis is the histopathological analysis of the affected bone 
(2). Histological features of SBP are sheets or clusters of 
atypical plasma cells with various types of differentia-
tion. These cells may present as mature plasma cells of 
normal spectrum or different degrees of maturity, from 
undifferentiated cells similar to lymphoid precursors 
(plasmacytoma) to intermediate forms between lym-
phocytes and plasma cells.  There are three different 
groups of differentiation, which are related to the rate of 
survival: 1) low dysplasia, with less than 10% of plas-
moblastos 2) moderate dysplasia, with 10-50% of plas-
moblastos, and 3) severe dysplasia with 50% of imma-
ture forms and worse prognosis than the others. These 
cells are round or oval with excentric nuclei, chromatin 
pattern “cartwheel” and acidophilic inclusions known 
as “Russell bodies” (5,8,9) . 
The primary treatment of SBP  is radiation therapy, radi-
cal extensive surgery, or both combined (8, 10). Radical 
radiotherapy is the treatment of choice at doses of 40-50 
Gy, showing an index of local disease control of 80%. 
There is no evedence of relationship for a 40-45 Gy dose 
response and tumor size (11). Surgical treatment is elec-
tive in those selected cases where all tumour is removed 
with minimal cosmetic or functional deficit or those to 
prevent or stabilize a pathologic mandibular fracture. 
The partial resection, with or without adjuvant radiothe-
rapy, has not been shown to decrease survival or local 
control compared to radiotherapy treatment isolated. 
The role of adjuvant chemotherapy is at present not 
clearly defined. The addition of chemotherapy to ra-
diotherapy in the treatment of SBP has not been shown 
to decrease local recurrence or increase survival rates 
compared to local treatment with radiotherapy alone, 
therefore, should be reserved for those cases progres-
sing to multiple myeloma (12,13). 
Currently, there is considerable interest in the role of an-
giogenesis inhibitors, thalidomide, protease inhibitors 
or inhibitors of vascular endothelium growth factor in 
plasma cell neoplasms, which could, in a future, be an 
alternative treatment (14). 
Between 35 and 85% of SBP progress to MM arising 
in a period of few months to years after diagnosis, in 
fact, some authors consider the SBP an early stage of 
the disseminated disease. It is not possible to predict 
which case may transform although there are some risk 
factors: age (> 60 years), M component levels > 20 g / 
L up to one year following radiotherapy, large tumour 
neovascularization and tumor size> 5 cm (this more dis-
cussed) (14,15). So after treatment, SPB cases must be 
closely followed up (1,2,5). 
The course of SPB is relatively benign and survival is 
50-80% at 10 years. The prognosis of solitary plasma-
cytoma is worse if recurrence is present as in cases of 
evolution toward systemic disease and survival at 10 
years is 16% and the average outliving is over 60-90 
months (1, 10-13).
 
Fig. 3. Histopathological image with different stains.
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Conclusions
1. Solitary bone plasmacytoma is a localized form of 
plasma cell tumours. Maxillofacial area it is rarely 
affected, most commonly the mandible.
2. This entity requires a meticulous overview of the pa-
tient by the specialist and overall the control of any sig-
ns or symptoms of systemic diseases, a fact that would 
mark a dramatic change in the treatment and prognosis 
of the patient. 
3. Treatment includes radiation therapy, radical extensi-
ve surgery, or both combined. Chemotherapy should be 
reserved for those cases progressing to multiple mye-
loma. 
4. The course of SPB is relatively benign and survival is 
50-80% at 10 years. The prognosis is worse if recurren-
ce is present as in cases of evolution toward systemic 
disease.
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